Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies

S. I. van Nes, Els K. Vanhoutte, Pieter A. van Doorn, +5

Neurology

Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain‐Barré syndrome

Krista Kuitwaard, Jenny de Gelder, Anne P. Tio‐Gillen, +5

Annals of Neurology

Recurrent Guillain-Barre syndrome

Krista Kuitwaard, Rinske van Koningsveld, Liselotte Ruts, +2

Journal of Neurology Neurosurgery & Psychiatry

Recurrences, vaccinations and long‐term symptoms in GBS and CIDP

Krista Kuitwaard, Martine E. Bos‐Eyssen, Patricia H. Blomkwist‐Markens, +1

Journal of the Peripheral Nervous System

Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial

Christa Walgaard, Bart C. Jacobs, Hester F. Lingsma, +101

The Lancet Neurology

ImmunodeficienciesImmunologyPlacebo-controlled TrialPoor PrognosisMultiple Sclerosis +2

Current treatment practice of Guillain-Barré syndrome

Christine Verboon, Alex Y. Doets, Giuliana Galassi, +180

Neurology

An International Perspective on Preceding Infections in Guillain-Barré Syndrome

Sonja E. Leonhard, Annemiek A. van der Eijk, Henning Andersen, +156

Neurology

Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study

Linda W.G. Luijten, Sonja E. Leonhard, Annemiek A. van der Eijk, +212

Brain

Recruitment BiasWorld Health OrganizationLong CovidSars-cov-2 InfectionNeurovirology +10

Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy

Krista Kuitwaard, P.A. van Doorn, M. Vermeulen, +10

Journal of Neurology Neurosurgery & Psychiatry

Association of Albumin Levels With Outcome in Intravenous Immunoglobulin–Treated Guillain-Barré Syndrome

Willem‐Jan R. Fokkink, Christa Walgaard, Krista Kuitwaard, +3

JAMA Neurology